ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 815,92
-1,49%
DAX
17 932,17
-1,10%
Brent Oil
85,57
-0,38%
Bitcoin
60 005,05
-0,98%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Seagen Inc (SGEN)

  7. Seagen Inc (SGEN) Actualités

SGEN Seagen Inc

228,74
0,00 (0,00%)
30 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Seagen Inc SGEN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 228,74 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
228,74 228,74
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
09/1/202412:12IHMARKETNEWSWall Street Highlights: HPE and Juniper Networks in..
26/12/202312:12EDGAR2Form 15-12G - Securities registration termination [Section..
19/12/202300:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202323:25EDGAR2Form SC 13D/A - General statement of acquisition of..
16/12/202300:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202323:00PRNUSPADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA®..
14/12/202314:47EDGAR2Form S-8 POS - Securities to be offered to employees in..
14/12/202314:29EDGAR2Form POSASR - Post-effective Amendment to an automatic shelf..
14/12/202314:00EDGAR2Form 8-K - Current report
14/12/202314:00EDGAR2Form 25-NSE - Notification filed by national security..
12/12/202314:32EDGAR2Form 8-K - Current report
12/12/202314:26DJFRPfizer prévoit de boucler l'acquisition de Seagen jeudi
12/12/202313:43DJNPfizer to Close $43 Billion Seagen Acquisition This Week
11/12/202301:30BWADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy..
06/12/202314:15BWTUKYSA® (tucatinib) in Combination with Antibody-Drug..
01/12/202300:04DJNAstellas, Seagen: Cancer Treatment Padcev Supplemental..
30/11/202323:00PRNUSFDA Grants Priority Review for Supplemental Biologics..
14/11/202303:37EDGAR2Form 144/A - Report of proposed sale of securities: [Amend]
14/11/202302:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202301:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202300:37EDGAR2Form 144 - Report of proposed sale of securities
09/11/202322:12EDGAR2Form 144 - Report of proposed sale of securities
03/11/202317:00BWSeagen Highlights First Solid Tumor Data for an ADCETRIS®..
02/11/202318:00BWNew Data for ADCETRIS® (brentuximab vedotin) with..
01/11/202313:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202313:09EDGAR2Form 8-K - Current report
01/11/202313:00BWSeagen Third Quarter 2023 Financial Results Reflect Strong..
22/10/202316:30BWTIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged..
20/10/202313:22IHMARKETNEWSFriday’s Wall Street Highlights: SolarEdge, Intuitive..
19/10/202317:14EDGAR2Form 8-K - Current report
16/10/202319:28DJFRPfizer détaille son plan d'économies après son..
16/10/202314:00BWSeagen to Highlight Overall Survival Data for PADCEV® and..
12/10/202314:00BWSeagen to Report Third Quarter 2023 Financial Results on..
23/9/202301:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/9/202301:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/9/202301:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/9/202301:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
SGEN
Seagen
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés